JP2009120598A5 - - Google Patents

Download PDF

Info

Publication number
JP2009120598A5
JP2009120598A5 JP2008273676A JP2008273676A JP2009120598A5 JP 2009120598 A5 JP2009120598 A5 JP 2009120598A5 JP 2008273676 A JP2008273676 A JP 2008273676A JP 2008273676 A JP2008273676 A JP 2008273676A JP 2009120598 A5 JP2009120598 A5 JP 2009120598A5
Authority
JP
Japan
Prior art keywords
group
pharmaceutically acceptable
solvate
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008273676A
Other languages
English (en)
Japanese (ja)
Other versions
JP4568779B2 (ja
JP2009120598A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2008273676A priority Critical patent/JP4568779B2/ja
Priority claimed from JP2008273676A external-priority patent/JP4568779B2/ja
Publication of JP2009120598A publication Critical patent/JP2009120598A/ja
Publication of JP2009120598A5 publication Critical patent/JP2009120598A5/ja
Application granted granted Critical
Publication of JP4568779B2 publication Critical patent/JP4568779B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008273676A 2007-10-26 2008-10-24 スピロ環化合物及びその医薬用途 Expired - Fee Related JP4568779B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008273676A JP4568779B2 (ja) 2007-10-26 2008-10-24 スピロ環化合物及びその医薬用途

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007279697 2007-10-26
JP2008273676A JP4568779B2 (ja) 2007-10-26 2008-10-24 スピロ環化合物及びその医薬用途

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010165678A Division JP2010270137A (ja) 2007-10-26 2010-07-23 スピロ環化合物及びその医薬用途

Publications (3)

Publication Number Publication Date
JP2009120598A JP2009120598A (ja) 2009-06-04
JP2009120598A5 true JP2009120598A5 (cg-RX-API-DMAC7.html) 2010-04-22
JP4568779B2 JP4568779B2 (ja) 2010-10-27

Family

ID=40579581

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2008273676A Expired - Fee Related JP4568779B2 (ja) 2007-10-26 2008-10-24 スピロ環化合物及びその医薬用途
JP2010165678A Pending JP2010270137A (ja) 2007-10-26 2010-07-23 スピロ環化合物及びその医薬用途
JP2014158380A Pending JP2014221829A (ja) 2007-10-26 2014-08-04 スピロ環化合物及びその医薬用途
JP2016001396A Ceased JP2016102130A (ja) 2007-10-26 2016-01-06 スピロ環化合物及びその医薬用途
JP2017049246A Pending JP2017132787A (ja) 2007-10-26 2017-03-14 スピロ環化合物及びその医薬用途

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2010165678A Pending JP2010270137A (ja) 2007-10-26 2010-07-23 スピロ環化合物及びその医薬用途
JP2014158380A Pending JP2014221829A (ja) 2007-10-26 2014-08-04 スピロ環化合物及びその医薬用途
JP2016001396A Ceased JP2016102130A (ja) 2007-10-26 2016-01-06 スピロ環化合物及びその医薬用途
JP2017049246A Pending JP2017132787A (ja) 2007-10-26 2017-03-14 スピロ環化合物及びその医薬用途

Country Status (29)

Country Link
US (3) US8299296B2 (cg-RX-API-DMAC7.html)
EP (3) EP2202216B1 (cg-RX-API-DMAC7.html)
JP (5) JP4568779B2 (cg-RX-API-DMAC7.html)
KR (1) KR101565622B1 (cg-RX-API-DMAC7.html)
CN (1) CN101835737B (cg-RX-API-DMAC7.html)
AR (1) AR071055A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008314933B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0818687A2 (cg-RX-API-DMAC7.html)
CA (1) CA2704013C (cg-RX-API-DMAC7.html)
CL (1) CL2008003153A1 (cg-RX-API-DMAC7.html)
CO (1) CO6321230A2 (cg-RX-API-DMAC7.html)
CY (1) CY1113352T1 (cg-RX-API-DMAC7.html)
DK (1) DK2202216T3 (cg-RX-API-DMAC7.html)
ES (1) ES2386596T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120696T1 (cg-RX-API-DMAC7.html)
IL (1) IL205283A (cg-RX-API-DMAC7.html)
ME (1) ME02338B (cg-RX-API-DMAC7.html)
MX (1) MX2010004435A (cg-RX-API-DMAC7.html)
MY (1) MY148469A (cg-RX-API-DMAC7.html)
NZ (1) NZ584161A (cg-RX-API-DMAC7.html)
PE (1) PE20091014A1 (cg-RX-API-DMAC7.html)
PL (1) PL2202216T3 (cg-RX-API-DMAC7.html)
PT (1) PT2202216E (cg-RX-API-DMAC7.html)
RS (1) RS52474B (cg-RX-API-DMAC7.html)
RU (1) RU2490250C2 (cg-RX-API-DMAC7.html)
SI (1) SI2202216T1 (cg-RX-API-DMAC7.html)
TW (1) TWI421070B (cg-RX-API-DMAC7.html)
WO (1) WO2009054479A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201002305B (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009012929A (es) * 2007-06-11 2009-12-14 Givaudan Sa Compuestos organicos.
TWI421070B (zh) * 2007-10-26 2014-01-01 Japan Tobacco Inc 螺化合物及其醫藥用途
NZ588983A (en) * 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
ES2416462T3 (es) * 2009-06-29 2013-08-01 Merz Pharma Gmbh & Co. Kgaa Método de preparación de neramexane.
JP5749259B2 (ja) 2009-06-29 2015-07-15 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー 1−クロロアセトアミド−1,3,3,5,5−ペンタメチルシクロヘキサンを調製する方法
EP2448901A1 (en) * 2009-06-29 2012-05-09 Merz Pharma GmbH & Co. KGaA Method of preparing 3,3,5,5-tetramethylcyclohexanone
EP2289881A1 (de) * 2009-08-06 2011-03-02 Boehringer Ingelheim International GmbH Verfahren zur stereoselektiven Synthese bicyclischer Heterocyclen
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
PH12012501456A1 (en) 2009-12-25 2012-10-29 Mochida Pharm Co Ltd Novel 3-hydroxy -5- arylisothiazole derivative
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
AU2011313191A1 (en) 2010-10-08 2013-05-02 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
GEP20156423B (en) 2011-02-01 2016-01-11 Boehringer Ingelheim Int 9-[4-(3-chlor-2-fluorphenylamino)-7-methoxy- quinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one dimaleate, usage thereas drug, and production thereof
AR085990A1 (es) 2011-04-27 2013-11-13 Mochida Pharm Co Ltd Derivados de 1-oxido de 3-hidroxiisotiazol utiles en el tratamiento de la diabetes y composiciones farmaceuticas que los contienen
JPWO2012147516A1 (ja) 2011-04-28 2014-07-28 持田製薬株式会社 環状アミド誘導体
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2015524400A (ja) 2012-07-19 2015-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 9−[4−(3−クロロ−2−フルオロ−フェニルアミノ)−7−メトキシ−キナゾリン−6−イルオキシ]−1,4−ジアザ−スピロ[5.5]ウンデカン−5−オンのフマル酸塩、その薬物としての使用及び調製
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
TWI692469B (zh) 2012-11-09 2020-05-01 南韓商Lg化學股份有限公司 Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
UY35143A (es) 2012-11-16 2014-05-30 Bristol Myers Squibb Co Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g
KR101569522B1 (ko) 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
WO2015084692A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
CA2935897C (en) 2014-02-19 2018-07-03 Piramal Enterprises Limited Compounds for use as gpr120 agonists
CA2955919A1 (en) 2014-07-25 2016-01-28 Piramal Enterprises Limited Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
EP3191463B1 (en) 2014-09-11 2019-10-30 Piramal Enterprises Limited Fused heterocyclic compounds as gpr120 agonists
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
US11186565B2 (en) 2017-03-31 2021-11-30 Takeda Pharmaceutical Company Limited Aromatic compound
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN115181023B (zh) * 2022-05-17 2023-07-28 东华理工大学 螺环活性增塑剂及其制备方法
CN121729216A (zh) * 2023-08-11 2026-03-24 生命密码有限公司 促进毛发生长和/或减轻脱发的组合物、药剂和制剂

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4331179A1 (de) * 1993-09-14 1995-03-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9927056D0 (en) 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
DE60315776T2 (de) * 2002-10-14 2008-06-05 Firmenich S.A. Spiroverbindungen als Duftstoffe
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
AU2003277576A1 (en) * 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
US8008525B2 (en) 2003-11-26 2011-08-30 Takeda Pharmaceutical Company Limited Receptor function regulating agent
JP4074616B2 (ja) 2003-12-25 2008-04-09 武田薬品工業株式会社 3−(4−ベンジルオキシフェニル)プロパン酸誘導体
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
EP1737809B1 (en) * 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US7582803B2 (en) 2005-09-14 2009-09-01 Amgen Inc. Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders
CA2662305C (en) 2006-09-07 2012-04-17 Amgen Inc. Heterocyclic gpr40 modulators
EP2061760A1 (en) 2006-09-07 2009-05-27 Amgen, Inc Benzo-fused compounds for use in treating metabolic disorders
TWI421070B (zh) * 2007-10-26 2014-01-01 Japan Tobacco Inc 螺化合物及其醫藥用途
NZ588983A (en) 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound

Similar Documents

Publication Publication Date Title
RU2490250C2 (ru) Спиросоединения и их фармацевтическое применение
NZ598085A (en) Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
JP2012512907A5 (cg-RX-API-DMAC7.html)
WO2007125405A3 (en) Substituted 2-amino-fused heterocyclic compounds
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
NZ602754A (en) Substituted 1,3-benzothiazepines useful in treating metabolic disorders
JP2010524932A5 (cg-RX-API-DMAC7.html)
JP2013510123A5 (cg-RX-API-DMAC7.html)
EP3404029A3 (en) Pyrimido-pyridazinone compounds and methods and use thereof
RU2009138600A (ru) Амиды диазабициклоалканов, селективные в отношении ацетилхолинового подтипа никотиновых рецепторов
NO20091244L (no) Adenosinderivater som A2A reseptoragonister
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
JP2014507477A5 (cg-RX-API-DMAC7.html)
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
WO2011045232A3 (en) Neuropeptide-2 receptor (y-2r) agonists
WO2010052144A3 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
JP2015508092A5 (cg-RX-API-DMAC7.html)
MX2011013648A (es) Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.
WO2010095768A8 (en) 4 -isopropylphenyl glucitol compounds as sglt1 inhibitors
JP2013537240A5 (cg-RX-API-DMAC7.html)
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
JP2017522304A5 (cg-RX-API-DMAC7.html)
WO2008098978A3 (en) Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
AU2025213600A1 (en) Nurr1 receptor modulators